Merck has therefore developed Prevymis (letermovir) to give another option, approved as a daily tablet or injection. The drug is expected to be available from next month, at a list price of $195 ...
Merck's Keytruda sales rose 17.2% YoY to $7.43 billion. Find out why MRK stock's strong fundamentals and high dividend yield ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback